|
CLINICA CAYANGA |
||
|
|
Rosiglitazone delays developing DM (DREAM) |
|
|
Alzheimer's
Disease Arthritis Asthma Benign Prostatic Hypertrophy Chronic Lymphocytic Leukemia Coronary Artery Disease Depression Diabetes Mellitus Dyspepsia Erectile Dysfunction Fatty Liver Gallstone Hepatitis Hypertension Lung Cancer Mesothelioma Metabolic Syndrome Obesity Pneumonia Pregnancy Prostate Cancer Sinusitis Stroke Tinnitus |
Clinical Question: Does rosiglitazone delay the development of diabetes in patients with impaired glucose tolerance or impaired fasting glucose levels? Bottom Line: Rosiglitazone at 8 mg daily for 3 years substantially reduces incident type 2 diabetes and increases the likelihood of regression to normoglycaemia in adults with impaired fasting glucose or impaired glucose tolerance, or both. Reference: DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105. Study Design: Randomized controlled trial (double-blinded) Synopsis: Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The authors assessed prospectively the drug's ability to prevent type 2 diabetes in individuals at high risk of developing the condition. 5269 adults aged 30 years or more with impaired fasting glucose or impaired glucose tolerance, or both, and no previous cardiovascular disease were recruited from 191 sites in 21 countries and randomly assigned to receive rosiglitazone (8 mg daily; n=2365) or placebo (2634) and followed for a median of 3 years. The primary outcome was a composite of incident diabetes or death. Analyses were done by intention to treat. This trial is registered at ClinicalTrials.gov, number NCT00095654. At the end of study, 59 individuals had dropped out from the rosiglitazone group and 46 from the placebo group. 306 (11.6%) individuals given rosiglitazone and 686 (26.0%) given placebo developed the composite primary outcome (hazard ratio 0.40, 95% CI 0.35-0.46; p<0.0001); 1330 (50.5%) individuals in the rosiglitazone group and 798 (30.3%) in the placebo group became normoglycaemic (1.71, 1.57-1.87; p<0.0001). Cardiovascular event rates were much the same in both groups, although 14 (0.5%) participants in the rosiglitazone group and two (0.1%) in the placebo group developed heart failure (p=0.01). |
|
|
Patient Information |
||
| Health For Life | ||
|
Medical Library |
||
|
Breaking Medical News Clinical Tools Coronary Risk Profile Dermatology Diabetes Corner Evidence-Based Medicine Free Medical Books Free Medical Journal History Taking and Physical Examination Hows on Making Diagnostic Examination Medical Journal (popular) Medical Organizations Medical Professional News Neurological and Psychiatric Problems in Clinical Practice Palm Tools Medical Notes Medical Physiology (Lecture) Medical Resources Medical Search Online Clinical Calculator Scientific Meeting |
||
| Online Sari-Sari Store | ||
Please
support Clinica Cayanga Medical Resources by purchasing gift items
at  |
||
|
Home | Introduction | Scheduling a Visit| Laboratory Work | Reaching Us | Map to our Office | About the Doctors |
||